Prognostic Impact of Concomitant Beta-Blocker Use on Survival in EGFR-Mutant Metastatic Non-Small Cell Lung Cancer Patients Treated with Erlotinib

<i>Background and Objectives</i>: Erlotinib, a tyrosine kinase inhibitor (TKI), is an established therapy for patients with metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. Preclinical and clinical evidence suggests that chronic s...

Full description

Bibliographic Details

Published in:	Medicina
Main Authors:	Oğuzhan Yıldız, Talat Aykut, Bahattin Engin Kaya, Ömer Genç, Ali Fuat Gürbüz, Fatih Saçkan, Melek Karakurt Eryılmaz, Mehmet Zahid Koçak, Murat Araz, Mehmet Artaç
Format:	Article
Language:	English
Published:	MDPI AG 2025-10-01
Subjects:	beta-blocker erlotinib EGFR-mutant metastatic non-small cell lung cancer survival
Online Access:	https://www.mdpi.com/1648-9144/61/10/1843